GSK (GSK) Stock Forecast & Price Target

GBX 1,429 -18.00 (-1.24%)

As of 12:16 PM Eastern

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
1

Hold
1

Buy
5

Based on 7 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, and 5 have given a buy rating for GSK.

Consensus Price Target

GBX 1,805.83

According to the 7 analysts' twelve-month price targets for GSK, the average price target is GBX 1,805.83. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,600. The average price target represents a forecasted upside of 26.37% from the current price of GBX 1,429.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 2/22/24 to 2/21/25	1 Month Ago 1/23/24 to 1/22/25	3 Months Ago 11/24/23 to 11/23/24	1 Year Ago 2/22/23 to 2/22/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 1,805.83	GBX 1,805.83	GBX 1,842.50	GBX 1,668.89
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies
Consensus Rating Score	2.57	2.82
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Positive News See Recent GSK News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/7/2025	JPMorgan Chase & Co. 2 of 5 stars		Reiterated Rating	Underweight
11/29/2024	Berenberg Bank 2 of 5 stars		Lower Target	Buy	GBX 1,820 ➝ GBX 1,600	+19.27%
9/3/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Reiterated Rating	Buy	GBX 1,850	+11.78%
8/28/2024	Shore Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
7/5/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	GBX 2,120 ➝ GBX 1,900	+24.79%
6/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	GBX 2,100	+38.25%
5/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	GBX 1,725	-1.96%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 1,440 ➝ GBX 1,585	+3.39%
7/17/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		GBX 1,450 ➝ GBX 1,390	+5.22%
3/6/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keyur Parekh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		GBX 2,000	+38.68%
Get the Latest News and Ratings for GSK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:37 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, February 19, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc has a strong market capitalization of £58.23 billion, indicating a robust financial position and stability, which can be attractive to investors looking for established companies.
The company reported earnings per share of GBX 23.20 ($0.29) recently, showcasing its profitability and ability to generate income for shareholders.
GSK plc's stock is currently trading at GBX 1,435 ($18.05), which is near its one-year low of GBX 1,282.50 ($16.13), potentially offering a buying opportunity for investors looking for undervalued stocks.
Analysts have given GSK plc a mix of ratings, with five analysts recommending a buy, suggesting positive sentiment and potential for growth in the stock price.
The company has a relatively low beta of 0.31, indicating lower volatility compared to the market, which can be appealing for risk-averse investors.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc has a high debt-to-equity ratio of 114.64, which may indicate that the company is heavily reliant on debt financing, posing risks if market conditions change.
The company has a quick ratio of 0.73 and a current ratio of 0.81, suggesting potential liquidity issues, as it may struggle to cover short-term liabilities with its current assets.
Recent insider selling, including a significant transaction by CEO Emma Walmsley, could raise concerns among investors about the company's future prospects and management confidence.
JPMorgan Chase & Co. has issued an "underweight" rating on GSK plc, indicating that some analysts believe the stock may underperform compared to the market.
The stock has experienced a decline of 0.7% recently, which may signal weakness in investor sentiment and could deter potential buyers.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,805.83, with a high forecast of GBX 2,100 and a low forecast of GBX 1,600.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There is currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 26.37% based on their 12-month stock forecasts.
: GSK has been rated by research analysts at Berenberg Bank, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.57 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (LON:GSK) was last updated on 2/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target